Show simple item record

dc.contributor.authorAnderson, Heather
dc.contributor.authorPalmer, Michael K
dc.date.accessioned2010-02-12T12:30:07Z
dc.date.available2010-02-12T12:30:07Z
dc.date.issued1998
dc.identifier.citationMeasuring quality of life: impact of chemotherapy for advanced colorectal cancer. Experience from two recent large phase III trials. 1998, 77 Suppl 2:9-14 Br. J. Canceren
dc.identifier.issn0007-0920
dc.identifier.pmid9579850
dc.identifier.urihttp://hdl.handle.net/10541/91994
dc.description.abstractWhen assessing the value of a particular treatment, it is important to consider the impact it may have on the quality of life of those being treated. This is particularly so for cancer patients, whose life expectancy may be short. Patients with advanced colorectal cancer who participated in two international comparative studies of raltitrexed ('Tomudex') vs standard 5-fluorouracil (5-FU) plus leucovorin (LV) completed previously validated quality-of-life questionnaires (EORTC questionnaire, EuroQol and Rotterdam Symptom Check List) at various times during the studies. Early statistically significant advantages of raltitrexed vs 5-FU plus LV on quality of life were observed at week 2 in five of eight of the EuroQol and three of four of the Rotterdam Symptom Check List dimensions. Such advantages were not observed using the EORTC questionnaire, which was not completed until week 12. The necessary dose delays and different dose schedules made it difficult in these studies to compare the impact on quality of life of the two treatments. It may be that performance status, effect on disease-related symptoms and the incidence of toxicity are the most important indications of a patient's quality of life.
dc.language.isoenen
dc.subjectColorectal Canceren
dc.subject.meshAnalysis of Variance
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshColorectal Neoplasms
dc.subject.meshEnzyme Inhibitors
dc.subject.meshFluorouracil
dc.subject.meshHumans
dc.subject.meshLeucovorin
dc.subject.meshQuality of Life
dc.subject.meshQuestionnaires
dc.subject.meshQuinazolines
dc.subject.meshThiophenes
dc.subject.meshThymidylate Synthase
dc.titleMeasuring quality of life: impact of chemotherapy for advanced colorectal cancer. Experience from two recent large phase III trials.en
dc.typeArticleen
dc.contributor.departmentChristie Hospital, Withington, Manchester, UK.en
dc.identifier.journalBritish Journal of Canceren
html.description.abstractWhen assessing the value of a particular treatment, it is important to consider the impact it may have on the quality of life of those being treated. This is particularly so for cancer patients, whose life expectancy may be short. Patients with advanced colorectal cancer who participated in two international comparative studies of raltitrexed ('Tomudex') vs standard 5-fluorouracil (5-FU) plus leucovorin (LV) completed previously validated quality-of-life questionnaires (EORTC questionnaire, EuroQol and Rotterdam Symptom Check List) at various times during the studies. Early statistically significant advantages of raltitrexed vs 5-FU plus LV on quality of life were observed at week 2 in five of eight of the EuroQol and three of four of the Rotterdam Symptom Check List dimensions. Such advantages were not observed using the EORTC questionnaire, which was not completed until week 12. The necessary dose delays and different dose schedules made it difficult in these studies to compare the impact on quality of life of the two treatments. It may be that performance status, effect on disease-related symptoms and the incidence of toxicity are the most important indications of a patient's quality of life.


This item appears in the following Collection(s)

Show simple item record